CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).
View Top Employees from CG OncologyWebsite | http://cgoncology.com |
Revenue | $10.6 million |
Funding | $45.6 million |
Employees | 74 (43 on RocketReach) |
Founded | 2010 |
Address | 400 Spectrum Center Drive Suite 2040, Irvine, California 92618, US |
Phone | (714) 884-3953 |
Fax | (949) 288-6298 |
Industry | Pharmaceuticals, Biotechnology, Biotechnology Research, Drug Discovery, Immunotherapy, Healthcare, Science and Engineering, Immuno-Oncology, Medical Device, Drug Manufacturing & Research, Health Care, Therapeutics |
Web Rank | 11 Million |
Keywords | Cold Genesys, Inc., Cold Genesys Cg0070 |
SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular CG Oncology employee's phone or email?
The CG Oncology annual revenue was $10.6 million in 2024.
Ursula Fritsch is the Chief Regulatory Officer of CG Oncology.
43 people are employed at CG Oncology.
CG Oncology is based in Irvine, California.
The NAICS codes for CG Oncology are [3254, 325, 32541, 32].
The SIC codes for CG Oncology are [2834, 283, 28].